Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation‐induced antigens (CD25 and CD69)
暂无分享,去创建一个
A. Zander | B. Fehse | O. Frerk | M. Goldmann | M. Bulduk | A. Zander | Boris Fehse | Oliver Frerk | Michal Goldmann | Maria Bulduk | Michal Goldmann
[1] A. Zander,et al. Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements , 1999, Gene Therapy.
[2] H. Prentice,et al. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis , 1999, Bone Marrow Transplantation.
[3] J. Román,et al. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft , 1999, Bone Marrow Transplantation.
[4] F. Marini,et al. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. , 1999, Transplantation.
[5] Raptis,et al. Specific depletion of alloreactive T cells in HLA‐identical siblings: a method for separating graft‐versus‐host and graft‐versus‐leukaemia reactions , 1998, British journal of haematology.
[6] H. Prentice,et al. Temporal dynamics of CD69 expression on lymphoid cells. , 1997, Journal of immunological methods.
[7] A. Zander,et al. Selective immunoaffinity-based enrichment of CD34+ cells transduced with retroviral vectors containing an intracytoplasmatically truncated version of the human low-affinity nerve growth factor receptor (deltaLNGFR) gene. , 1997, Human gene therapy.
[8] C. Bordignon,et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.
[9] P. Ricciardi-Castagnoli,et al. Dendritic cells hold promise for immunotherapy. , 1997, Immunology today.
[10] A. Balsari,et al. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. , 1997, Cytometry.
[11] J. Hurwitz,et al. Eliminating graft-versus-host potential from T cell immunotherapeutic populations. , 1996, Bone marrow transplantation.
[12] A. Barrett,et al. GRAFT‐VERSUS‐LEUKAEMIA: UNDERSTANDING AND USING THE ALLOIMMUNE RESPONSE TO TREAT HAEMATOLOGICAL MALIGNANCIES , 1996, British journal of haematology.
[13] I. Pastan,et al. Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. , 1996, Bone marrow transplantation.
[14] A Ferrant,et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.
[15] A. Barrett,et al. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. , 1994, Bone marrow transplantation.
[16] Craig W. Reynolds,et al. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? , 1994, Blood.
[17] M. Ladanyi,et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.
[18] F. Sallusto,et al. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.
[19] H. Lother,et al. Homodimeric murine interleukin-3 agonists indicate that ligand dimerization is important for high-affinity receptor complex formation. , 1994, Growth factors.
[20] S. Riddell,et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.
[21] A. Freedman,et al. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. , 1992, Journal of Clinical Oncology.
[22] R. Macklis,et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. , 1991, Blood.
[23] R. Truitt,et al. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. , 1991, Bone marrow transplantation.
[24] W. Wilmanns,et al. Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients , 1990 .
[25] S. Feig,et al. Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. , 1990, Blood.
[26] A. Fischer,et al. SPECIFIC ELIMINATION OF ALLOREACTIVE T CELLS BY AN ANTI‐INTERLEUKIN-2 RECEPTOR B CHAIN‐SPECIFIC IMMUNOTOXIN , 1990, Transplantation.
[27] J. Wagner,et al. Bone marrow graft engineering by counterflow centrifugal elutriation: results of a phase I-II clinical trial. , 1990, Blood.
[28] A. Rimm,et al. Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.
[29] W. Wilmanns,et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.
[30] K. Sullivan,et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. , 1989, The New England journal of medicine.
[31] R. Good,et al. TRANSPLANTATION FOR ACUTE LEUKAEMIA WITH HLA-A AND B NONIDENTICAL PARENTAL MARROW CELLS FRACTIONATED WITH SOYBEAN AGGLUTININ AND SHEEP RED BLOOD CELLS , 1981, The Lancet.